R
Robin M. Murray
Researcher at King's College London
Publications - 1583
Citations - 128883
Robin M. Murray is an academic researcher from King's College London. The author has contributed to research in topics: Psychosis & Schizophrenia. The author has an hindex of 171, co-authored 1539 publications receiving 116362 citations. Previous affiliations of Robin M. Murray include University of Cambridge & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Globally Efficient Brain Organization and Treatment Response in Psychosis: A Connectomic Study of Gyrification.
Lena Palaniyappan,Lena Palaniyappan,Tiago Reis Marques,Heather Taylor,Valeria Mondelli,Valeria Mondelli,A. A. T. Simone Reinders,Stefania Bonaccorso,Annalisa Giordano,Annalisa Giordano,Marta DiForti,Andrew Simmons,Anthony S. David,Anthony S. David,Carmine M. Pariante,Carmine M. Pariante,Robin M. Murray,Paola Dazzan,Paola Dazzan +18 more
TL;DR: A perturbed maturational relationship among brain regions underlies poor treatment response in first-episode psychosis and the information obtained from gyrification-based connectomes can be harnessed for prospectively predicting treatment response and prognosis in psychosis.
Journal ArticleDOI
In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole: a 123I IBZM single photon emission tomography (SPET) study
Lyn S. Pilowsky,P. O’Connell,N. Davies,Geraldo F. Busatto,Durval C. Costa,Robin M. Murray,Peter J. Ell,Robert Kerwin +7 more
TL;DR: The preliminary evidence suggests that sertindole’s decreased tendency to induce EPS at clinically therapeutic doses is not due to limited occupancy of striatal D2 receptors in vivo, and as is the case for risperidone, patients are protected from EPS by some other intrinsic effect of the drug.
Journal ArticleDOI
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
Diego Quattrone,Laura Ferraro,Giada Tripoli,Caterina La Cascia,Harriet Quigley,Andrea Quattrone,Hannah E. Jongsma,Simona Del Peschio,Giusy Gatto,Charlotte Gayer-Anderson,Peter B. Jones,James B. Kirkbride,Daniele La Barbera,Ilaria Tarricone,Domenico Berardi,Sarah Tosato,Antonio Lasalvia,Andrei Szöke,Celso Arango,Miquel Bernardo,Julio Bobes,Cristina Marta Del Ben,Paulo Rossi Menezes,Pierre-Michel Llorca,Jose Luis Santos,Julio Sanjuán,Andrea Tortelli,Eva Velthorst,Lieuwe de Haan,Bart P. F. Rutten,Michael T. Lynskey,Tom P. Freeman,Pak C. Sham,Alastair G. Cardno,Evangelos Vassos,Jim van Os,Craig Morgan,Ulrich Reininghaus,Cathryn M. Lewis,Robin M. Murray,Marta Di Forti +40 more
TL;DR: These findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potencies types.
Journal ArticleDOI
Further evidence for shared genetic effects between psychotic bipolar disorder and P50 suppression: a combined twin and family study.
Mei-Hua Hall,Katja Schulze,Pak C. Sham,Sridevi Kalidindi,Colm McDonald,Elvira Bramon,Deborah L. Levy,Robin M. Murray,Fruhling Rijsdijk +8 more
TL;DR: Bipolar disorder was significantly associated with a diminished P50 suppression ratio and decreased C–T amplitude difference and shared genetic factors were the main source of these associations.
Journal ArticleDOI
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.
TL;DR: In this paper, the authors suggest that when antipsychotics are reduced, it should be done gradually (over months or years) and in a hyperbolic manner (to reduce D2 blockade "evenly"): i.e., reducing by one quarter (or one half) of the most recent dose of antipsychotic, equivalent approximately to a reduction of 5 (or 10) percentage points of its D2 receptor blockade, sequentially (so that reductions become smaller and smaller in size as total dose decreases), at intervals of 3-6 months, titrated to individual tolerance